TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07247188: A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 2-arm Study to Investigate the Safety and Immunogenicity of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Ado

Sponsor: Sanofi · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$11,659,620

Rescue Site Savings

+$7,691,430

Unlock Full NCT07247188 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07247188 Rescue Dossier →